Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of nonacog beta pegol in previously untreated children with hemophilia B
MOH_2017-06-20_000527Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nonacog beta pegol in hemophilia B (HB), sponsored by Novo Nordisk. Started Apr 2014; status: completed.
02
Drugs
nonacog beta pegol
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on MOH_2017-06-20_000527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-20_000527.